Roswell Park recognizes that it takes external business relationships to ultimately translate its discoveries into useful patient therapies; and actively encourages these agreements. Explore our inventory in the Technology Directory. To discuss licensing opportunities, contact our Technology Transfer Office today!
Protul Shrikant, PhD
mTOR Inhibition for Enhancing Cancer Vaccines - Recruiting the immune system to target cancer is attractive. The immune system is capable of recognizing tumor-specific antigens and eradicating diseased cells while sparing normal tissue. We have developed a method for enhancing the activity of cancer vaccines. The method consists of administering a cancer vaccine and an mTOR (mammalian target of rapamycin) inhibitor such as rapamycin and temsirolimus to an individual. Roswell Park has a current Phase I clinical trial in process using rapamycin to enhance NY-ESO-1 stimulation of isolated dendritic cells re-introduced into cancer patients.